Cited 14 times in
Clinical Perspectives to Overcome Acquired Resistance to Anti-Programmed Death-1 and Anti-Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김혜련 | - |
dc.contributor.author | 이기쁨 | - |
dc.contributor.author | 이용준 | - |
dc.date.accessioned | 2021-09-29T00:40:05Z | - |
dc.date.available | 2021-09-29T00:40:05Z | - |
dc.date.issued | 2021-05 | - |
dc.identifier.issn | 1016-8478 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/183977 | - |
dc.description.abstract | Immune checkpoint inhibitors have changed the paradigm of treatment options for non-small cell lung cancer (NSCLC). Monoclonal antibodies targeting programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) have gained wide attention for their application, which has been shown to result in prolonged survival. Nevertheless, only a limited subset of patients show partial or complete response to PD-1 therapy, and patients who show a response eventually develop resistance to immunotherapy. This article aims to provide an overview of the mechanisms of acquired resistance to anti-PD-1/PD-L1 therapy from the perspective of tumor cells and the surrounding microenvironment. In addition, we address the potential therapeutic targets and ongoing clinical trials, focusing mainly on NSCLC. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | Korean Society for Molecular and Cellular Biology | - |
dc.relation.isPartOf | MOLECULES AND CELLS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Clinical Perspectives to Overcome Acquired Resistance to Anti-Programmed Death-1 and Anti-Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Yong Jun Lee | - |
dc.contributor.googleauthor | Jii Bum Lee | - |
dc.contributor.googleauthor | Sang-Jun Ha | - |
dc.contributor.googleauthor | Hye Ryun Kim | - |
dc.identifier.doi | 10.14348/molcells.2021.0044 | - |
dc.contributor.localId | A01166 | - |
dc.relation.journalcode | J02273 | - |
dc.identifier.eissn | 0219-1032 | - |
dc.identifier.pmid | 34001680 | - |
dc.subject.keyword | acquired resistance | - |
dc.subject.keyword | immune checkpoint inhibitors | - |
dc.subject.keyword | non-small cell lung cancer | - |
dc.subject.keyword | programmed death ligand-1 | - |
dc.subject.keyword | programmed death-1 | - |
dc.contributor.alternativeName | Kim, Hye Ryun | - |
dc.contributor.affiliatedAuthor | 김혜련 | - |
dc.citation.volume | 44 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 363 | - |
dc.citation.endPage | 373 | - |
dc.identifier.bibliographicCitation | MOLECULES AND CELLS, Vol.44(5) : 363-373, 2021-05 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.